Even though MEK inhibitors, such as trametinib, have been extensively investigated, whether ERK inhibitors can be used for the treatment of iCCA, especially for KRAS-mutated iCCA, has not been properly evaluated in vivo or in vitro. The gene discussed is MAP2K7; the disease is infantile convulsions and choreoathetosis.